Glivec 400mg Tablet contains Imatinib mesylate, a selective tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer. It is indicated for the management of chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), gastrointestinal stromal tumors (GIST), and other malignancies characterized by specific tyrosine kinase abnormalities. Imatinib mesylate functions by inhibiting the BCR-ABL tyrosine kinase enzyme, which is produced by the Philadelphia chromosome abnormality in CML, thereby preventing the proliferation of malignant cells. Additionally, it targets other tyrosine kinases such as c-KIT and PDGF receptors involved in GIST pathogenesis. Glivec is administered orally, and the dosage is determined based on the specific indication and patient response. Common adverse effects include edema, nausea, muscle cramps, rash, and fatigue, while serious side effects may involve myelosuppression, hepatotoxicity, and cardiotoxicity, necessitating regular monitoring of blood counts and liver function tests during therapy. Glivec should be used under strict medical supervision, with attention to potential drug interactions and contraindications. Patient adherence to prescribed dosing schedules is critical to achieving optimal therapeutic outcomes in the management of tyrosine kinase-driven malignancies.